IL-33 blockade using the IL-33 neutralizing antibody or the ST2 neutralizing antibody resulted in reduced proliferative survival of NSCLC cells and diminished regulatory T cells (Treg) cells in tumor tissues [2]. This evidence concerns the gene IL1RL1 and non-small cell lung carcinoma.